1. Xu, Min, Zheng, Jie, Hou, Tianzhichao, Bi, Yufang, Wang, Weiqing. . SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study. In Diabetes care, 45, 2718-2728. doi:10.2337/dc22-0323. https://pubmed.ncbi.nlm.nih.gov/36161993/
2. Li, Jiang, Yu, Yuefeng, Sun, Ying, Lu, Yingli, Wang, Ningjian. 2023. SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study. In Cardiovascular diabetology, 22, 278. doi:10.1186/s12933-023-02019-8. https://pubmed.ncbi.nlm.nih.gov/37848934/
3. Rieg, Timo, Vallon, Volker. 2018. Development of SGLT1 and SGLT2 inhibitors. In Diabetologia, 61, 2079-2086. doi:10.1007/s00125-018-4654-7. https://pubmed.ncbi.nlm.nih.gov/30132033/
4. Fang, Xinyi, Miao, Runyu, Wei, Jiahua, Wu, Haoran, Tian, Jiaxing. 2022. Advances in multi-omics study of biomarkers of glycolipid metabolism disorder. In Computational and structural biotechnology journal, 20, 5935-5951. doi:10.1016/j.csbj.2022.10.030. https://pubmed.ncbi.nlm.nih.gov/36382190/
5. Xu, Bo, Li, Shaoqian, Kang, Bo, Tang, Fan, Zhou, Jiecan. 2023. Role of SLC5A2 polymorphisms and effects of genetic polymorphism on sodium glucose cotransporter 2 inhibitorsinhibitor response. In Molecular biology reports, 50, 9637-9647. doi:10.1007/s11033-023-08836-0. https://pubmed.ncbi.nlm.nih.gov/37819499/
6. Tomita, Issei, Kume, Shinji, Sugahara, Sho, Araki, Shin-Ichi, Maegawa, Hiroshi. 2020. SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition. In Cell metabolism, 32, 404-419.e6. doi:10.1016/j.cmet.2020.06.020. https://pubmed.ncbi.nlm.nih.gov/32726607/
智鼠故事 
